Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy

Journal of Infectious Diseases

Volumn 183, Issue 10, 2001, Pages 1455-1465

  Huang, W ^a   De Gruttola, V ^a   Fischl, M ^b   Hammer, S ^c   Richman, D ^e   Havlir, D ^e   Gulick, R ^d   Squires, K ^f   Mellors, J ^g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d Department of Obstetrics Gynecology   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f LAC USC MEDICAL CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE;

EID: 0035873216     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/320192     Document Type: Article

References (23)

1. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
2. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
3. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
4. Ultrasensitive reverse transcription - PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma
5. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
6. Randomized trial of abacavir in combination with indinavir and efavirenz in HIV-infected patients with nucleoside analog experience
7. Salvage therapy with saquinavir sgc in combination with ritonavir or nelfinavir plus delavirdine, adefovir, or both
8. A randomized placebo-controlled trial of saquinavir sgc, indinavir or nelfinavir in combination with amprenavir, abacavir, efavirenz and adefovir in patients with protease inhibitor failure
9. Regression models and life tables
10. On the treatment of grouped observations in life studies
11. Maximum likelihood estimation from incomplete data via the EM algorithm
12. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
13. Predictors of optimal virological response to potent antiretroviral therapy
14. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
15. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
16. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
17. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy: Pharmacologic data from the Viradapt study
18. Indinavir concentrations and antiviral effect
19. Pharmacodynamics of indinavir in protease-naive HIV-infected patients receiving ZDV and 3TC
20. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
21. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
22. Virologic failure during combination therapy with crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only